Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Gastrinoma 2Adenoma, Islet Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Rectal Neoplasms 1Rare Diseases 1Oligodendroglioma 1Insulinoma 1Glucagonoma 1Glioma 1Glioblastoma 1Genetic Diseases, Inborn 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Brain Neoplasms 1Astrocytoma 1Adrenocortical Carcinoma 1

Interventions

Everolimus 5Octreotide 4Leucovorin 4Temozolomide 3Oxaliplatin 3Fluorouracil 3Capecitabine 3vatalanib 2temsirolimus 2Trastuzumab 2Sirolimus 2Melphalan 2Irinotecan 2Biological Therapy 2Bevacizumab 2tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1napabucasin 1motesanib diphosphate 1irinotecan sucrosofate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Vinorelbine 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Islet Cell × Streptozocin × Clear all
NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡